Gerresheimer (OTCMKTS:GRRMF – Get Free Report) is expected to issue its results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.3166 per share and revenue of $671.32 million for the quarter.
Gerresheimer Price Performance
Gerresheimer stock opened at $37.47 on Monday. The company’s 50 day simple moving average is $31.75 and its 200 day simple moving average is $29.60. Gerresheimer has a fifty-two week low of $19.16 and a fifty-two week high of $37.47.
Analyst Ratings Changes
Several research firms have weighed in on GRRMF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Gerresheimer in a report on Tuesday, August 4th. UBS Group raised shares of Gerresheimer from a “sell” rating to a “neutral” rating in a report on Tuesday, August 4th. Four investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Gerresheimer presently has an average rating of “Reduce”.
View Our Latest Research Report on GRRMF
About Gerresheimer
Gerresheimer AG is a Germany-based manufacturer of pharmaceutical and healthcare packaging and drug-delivery systems. The company develops and produces primary packaging and components used to protect, store and administer medicines, serving pharmaceutical, biotechnology and healthcare customers worldwide.
Its product portfolio includes glass and plastic containers such as vials, ampoules, bottles, cartridges and syringes, as well as delivery systems including inhalers, injection pens, autoinjectors and other medical devices.
Featured Articles
- Five stocks we like better than Gerresheimer
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.
